NBIX News and Press, Neurocrine Biosciences Inc. From 01/25/23

Summary Expect strong Neurocrine Biosciences, Inc. Q4 results on February 6, 2023. Two important pipeline results regarding congenital adrenal hyperplasia and focal onset seizures will be coming this February. The FDA accepted Neurocrine Biosciences' sNDA for valbenazine as a treatm...

Summary After a strong performance in H2 FY22, Neurocrine Biosciences saw a sharp reversal into the new year. The question is, does this present an opportunity to buy or not? Market data suggests demand is still present and buyers have been active at these prices. We see scope f...

Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports and conference presentations. ...

Shares of the gene therapy company Voyager Therapeutics (NASDAQ: VYGR) were down by a little over 18% from their intraweek high as of 11:44 a.m. ET Friday, according to data provided by S&P Global Market Intelligence . Fortunately, the biotech's shares aren't falling in response t...

Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2022 Financial Results PR Newswire Conference Call and Webcast Scheduled for Monday, February 6 SAN DIEGO , Jan. 17, 2023 /PRNewswire/ -- Neurocrine Bioscience...

Summary A number of VBR "green energy" picks have popped higher in January, pulling investment returns for the group of past picks strongly higher. A performance review of 46 previous selections since late June is discussed. I continue to refine the search and formula ideas for iden...

Summary In trying to deliver breakthrough, Voyager Therapeutics is able to ink multiple robust deals with reputable companies. The company is trying to tackle some of the most difficult to treat neurological conditions like Alzheimer's disease, ALS, and Parkinson's. The recent Neuro...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: shutterstock.com/Romix Image Why is Voyager Therapeutics (NASDAQ: VYGR ) stock today up while Neurocrine Biosciences (NASDAQ: NBIX ) is down? Evidently, today’s movement is because of a deal between t...

- Voyager to receive up-front consideration of $175 million including a $39 million equity investment, up to $1.5 billion in potential development milestones, additional potential commercial milestones, tiered royalties on net sales, program funding, and an option to elect 50/50 cost- and profit-...

Summary BMEZ’s portfolio has a combination of unknown small-cap "next generation" healthcare holdings and some familiar names in the field of biotechnology. Lack of diversification makes BMEZ susceptible to sector-specific risk. It also has a relatively high expense ratio despite...